Company Ind-Swift Laboratories Limited Bombay S.E.

INDSWFTLAB

INE915B01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2026-07-02 EDT			5-day change	1st Jan Change
206.20 ^INR	+2.71%		+2.51%	+133.81%

06-22	Ind-Swift Laboratories Limited Announces Resignation of Prabhat Khurana as Independent Director and Committees, Effective June 22, 2026	CI
05-28	Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI

Business description: Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Companyâ€™s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.

Number of employees: 1,246

Sales by Activity: Ind-Swift Laboratories Limited

Fiscal Period: March	2021 (INR)	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)
Pharmaceutical Business	9.07B	10.52B	12.16B	12.97B	5.62B

See all business segments

Geographical breakdown of sales: Ind-Swift Laboratories Limited

Fiscal Period: March	2021 (INR)	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)
Export	6.72B	7.96B	9.37B	10.02B	4.06B
India	2.19B	2.43B	2.7B	2.79B	1.56B
Unallocated	227M	-	-	-	-

See all geographic segments

Executive Committee: Ind-Swift Laboratories Limited

Manager	Title	Age	Since
Navrattan R. Munjal CEO	Chief Executive Officer	74	1995-01-03
Himanshu Jain CEO	Chief Executive Officer	43	2011-06-14
Gagan Aggarwal DFI	Director of Finance/CFO	-	2018-09-28
Ashok Kothari CTO	Chief Tech/Sci/R&D Officer	-	2017-03-31
Pardeep Verma CMP	Compliance Officer	-	2012-10-10

See IND-SWIFT LABORATORIES LIMITED governance

Composition of the Board of Directors: Ind-Swift Laboratories Limited

Director	Title	Age	Since
Himanshu Jain BRD	Director/Board Member	43	-
Navrattan R. Munjal CHM	Chairman	74	-
Rishav Mehta BRD	Director/Board Member	35	2010-03-22
Neerja Chathley BRD	Director/Board Member	71	2019-05-09
Sahil Munjal BRD	Director/Board Member	45	2020-02-12
Rajinder Kumar Gupta BRD	Director/Board Member	70	2021-06-22
Subodh Gupta BRD	Director/Board Member	-	2025-07-04

Composition of the Board of Directors

Shareholders: Ind-Swift Laboratories Limited

Name	Stocks	%	Valuation
IND-SWIFT LABORATORIES LIMITED 37.87 %	32,882,521	37.87 %	53 M ₹
Zeal Asset Management Ltd. 4.622 %	4,013,561	4.622 %	6 M ₹
Ashok Kumar Chandak 2.813 %	2,442,449	2.813 %	4 M ₹
Panchkula Finvest Pvt Ltd. 2.408 %	2,091,079	2.408 %	3 M ₹
Pranav Joneja 1.386 %	1,203,700	1.386 %	2 M ₹

List of IND-SWIFT LABORATORIES LIMITED shareholders

Holdings: Ind-Swift Laboratories Limited

Name	Stocks	%	Valuation
IND-SWIFT LABORATORIES LIMITED 37.87%	32,882,521	37.87%	53 M $

Company details: Ind-Swift Laboratories Limited

Ind-Swift Laboratories Ltd.

SCO 850, Shivalik Enclave

160101, Manimajra

+91 17 2506 1850

http://www.indswiftlabs.com

address Ind-Swift Laboratories Limited(INDSWFTLAB)

Generic Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.26%	+0.44%	+11.54%	+77.92%	47.1B
OTSUKA HOLDINGS CO., LTD.	0.00%	+6.10%	+69.53%	+118.53%	34.57B
CIPLA LIMITED	-0.05%	+1.10%	-2.78%	+43.46%	12.38B
ZYDUS LIFESCIENCES LIMITED	-0.85%	-0.15%	+10.49%	+88.63%	11.64B
KRKA, D. D.	+2.59%	-1.91%	+32.47%	+121.55%	8.87B
GEDEON RICHTER	-0.08%	-0.25%	+22.32%	+43.82%	7.1B
ONO PHARMACEUTICAL CO., LTD.	+1.62%	+2.63%	+54.92%	-6.28%	6.85B
GLENMARK PHARMACEUTICALS LIMITED	+1.58%	+1.93%	+24.07%	+224.85%	6.42B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+6.55%	+16.24%	-23.92%	+16.83%	5.61B
Average	+1.25%	+2.19%	+22.07%	+81.03%	15.61B
Weighted average by Cap.	+0.51%	+0.34%	+27.59%	+86.96%